last week, glaxo smith kline was granted accelerated approval for a combination melanoma treatment. still, as more drugs enter the fda's expedited review programs, especially those breakthrough therapies, some worry these pipelines could strain fda resources. >> one thing to keep in mind is the fda resources in helping these drugs. this could still be especially an issue or something to watch. >> reporter: and of course, entrance into one of these programs does not guarantee a drug success. prioritized drugs can sometimes fuel a steep selloff in the drugmaker's stock. a risk especially inherent for the smaller less diversified biotech companies. for "nightly business report" i'm morgan brennan. >> coming up, it's just two weeks into the year. the new year. how many of you have already given up on your financial resolutions? we'll show you how to make them stick. >>> finally tonight, fidelity invest ntss says more than half after consumers plan to make a financial resolution this year, the most ever. most people want to save more. others want to pay off debt. and within in five plan